Eisai saw the highest growth of 1.17% in patent filings and 3.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of Eisai‘s patent filings and grants. Buy the databook here.
Eisai has been focused on protecting inventions in China(CN) with 13 publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 19% filings and 21% grants. The China(CN), European Patent Office(EPO), South Korea(KR), and Japan(JP) patent Office are among the top ten patent offices where Eisai is filings its patents. Among the top granted patent authorities, Eisai has 21% of its grants in China(CN), 21% in Japan(JP) and 21% in Israel(IL).
Roche and Johnson & Johnson could be the strongest competitors for Eisai
Patents related to climate change and addiction lead Eisai's portfolio
Eisai has the highest number of patents in climate change followed by, addiction and rare diseases. For climate change, nearly 71% of patents were filed and no patents were granted in Q2 2024.
Alzheimer's disease related patents lead Eisai portfolio followed by bile duct cancer (cholangiocarcinoma), and breast cancer
Eisai has highest number of patents in alzheimer's disease followed by bile duct cancer (cholangiocarcinoma), breast cancer, solid tumor, and petrochemicals.
For comprehensive analysis of Eisai's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.